CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Prevention of Tuberculosis Reactivation: Clinical Utility and Guidelines

Last updated: July 14, 2020
Project Number: RB1504-000
Product Line: Rapid Response
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical utility of screening for latent tuberculosis infection in people at risk of tuberculosis reactivation?
  2. What is the clinical utility of treating latent tuberculosis infection to prevent tuberculosis reactivation?
  3. What are the evidence-based guidelines for the prevention of tuberculosis reactivation?

Key Message

One network meta-analysis and one non-randomized study were identified regarding the clinical utility of treating latent tuberculosis infection to prevent tuberculosis reactivation. Two evidence-based guidelines were identified regarding the prevention of tuberculosis reactivation. No literature was identified regarding the clinical utility of screening for latent tuberculosis infection in people at risk of tuberculosis reactivation.